药物对比
Linagliptin vs Insulin Icodec
比较 Linagliptin（Tradjenta）与 Insulin Icodec（Awiqli）治疗2型糖尿病。口服与每周注射：作用机制、获益、风险和适用性。
此页面暂无可用的对比维度。
临床背景
This comparison arises for type 2 diabetes patients on oral agents considering insulin start or evaluating DPP-4 inhibitors against basal insulin therapy.
结论
Linagliptin offers convenient oral dosing with modest efficacy and low hypo risk for earlier T2D, whereas Insulin Icodec delivers potent weekly basal coverage for those requiring insulin intensification.
全部药物对比